RDHL Redhill Biopharma Ltd.

6.52
+0.2  (+3%)
Previous Close 6.32
Open 6.32
Price To Book 10.03
Market Cap 229,957,570
Shares 35,269,566
Volume 193,421
Short Ratio
Av. Daily Volume 315,641
Stock charts supplied by TradingView

NewsSee all news

  1. RedHill Biopharma to Present at Upcoming Investor Conferences in September

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 27, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated 4Q 2019.
RHB-204
Nontuberculous mycobacteria (NTM) infections
Phase 2a enrolment to be completed 2H 2019.
YELIVA
Cholangiocarcinoma
Phase 1/2 poster presentation at EORTC-NCI-AACR November 16, 2018.
YELIVA
Refractory or relapsed multiple myeloma - cancer
Phase 3 data released July 30, 2018. Primary endpoint met but further trial required. Phase 3 MAP US2 open label trial data due 4Q 2019.
RHB-104 MAP US2
Crohn’s disease
FDA Approval announced November 4, 2019.
Talicia RHB-105
H. pylori
Phase 3 top-line data released June 14, 2017 - primary endpoint met. Additional Phase 3 trial planned.
BEKINDA -GUARD
Gastroenteritis
Phase 2 top-line data released October 3, 2017 - primary endpoint met (borderline) - p=0.05. Follow up analysis identfied p value = 0.036. Phase 3 trial planned.
BEKINDA
IBS-D
Phase 2 initiated October 2016.
YELIVA
Hepatocellular carcinoma (HCC) - cancer

Latest News

  1. RedHill Biopharma to Present at Upcoming Investor Conferences in September

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 27, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily